Adding Liraglutide to Insulin Over 12 Weeks Reduced Weekly Glucose Levels

Share this content:
The findings do not justify the use of liraglutide for all type 1 diabetes patients.
The findings do not justify the use of liraglutide for all type 1 diabetes patients.

(HealthDay News) – For patients with type 1 diabetes, addition of 1.2 and 1.8 mg of liraglutide to insulin over a 12-week period is associated with a modest reduction in weekly mean glucose levels, according to a study published in Diabetes Care.

Nitesh D. Kuhadiya, MD, MPH, from State University of New York at Buffalo, and colleagues randomized 72 patients with type 1 diabetes to receive placebo (18 patients) and 0.6, 1.2, and 1.8 mg of liraglutide (54 patients) daily for 12 weeks.

 

The researchers observed a significant mean weekly reduction in average blood glucose in the 1.2- and 1.8-mg groups (P<.0001); the average blood glucose remained unchanged in the 0.6-mg and placebo groups. Hemoglobin A1c was reduced significantly in the 1.2-mg group (P<.01), but not in the 1.8- or 0.6-mg groups compared with placebo. In the 1.2-mg group only, glycemic variability was significantly reduced (P<.01). In the 1.2-mg and 1.8-mg groups, total daily insulin dose decreased significantly (P<.05). Weight loss was 5 ± 1 kg in the 1.2- and 1.8-mg groups (P<.05) and 2.7 ± 0.6 kg (P<.01) in the 0.6-mg group, compared with none in the placebo group. Higher gastrointestinal adverse events were seen with liraglutide (P<.05).

"These findings do not justify the use of liraglutide in all patients with type 1 diabetes," the authors write.

Several authors disclosed financial ties to biopharmaceutical companies, including Novo Nordisk, which manufactures liraglutide and funded the study.

Reference

  1. Kuhadiya ND, Dhindsa S, Ghanim H, et al. Addition of liraglutide to insulin in patients with type 1 diabetes: A randomized placebo-controlled clinical trial of 12 weeks. Diabetes Care. 2016; doi:10.2337/dc15-1136.
You must be a registered member of Endocrinology Advisor to post a comment.

Sign Up for Free e-Newsletters

CME Focus